keep away from moisture
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
iRGD Peptide 1 TFA is a prototypic tumor-homing peptide with tissue-penetrating capabilities, facilitating deep delivery of therapeutic agents into extravascular tumor tissue. Additionally, it possesses anti-metastatic activity [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry | |
50 mg | Inquiry | Inquiry |
Description | iRGD Peptide 1 TFA is a prototypic tumor-homing peptide with tissue-penetrating capabilities, facilitating deep delivery of therapeutic agents into extravascular tumor tissue. Additionally, it possesses anti-metastatic activity [1]. |
In vitro | The iRGD peptide 1 (iRGD) attenuates tumor cell migration and elicits chemorepulsion in vitro, contingent upon CendR and NRP-1 pathways. This peptide precipitates marked retraction of cell extensions and partial cell detachment, contributing to its repellent effect. Such responses are notably accentuated upon fibronectin exposure, implying CendR's instrumental role in modulating integrin activity [1]. |
In vivo | The iRGD peptide 1 (CRGDKGPDC; 4 μmol/kg; intravenous; qod; 21 days) effectively suppresses spontaneous metastasis in mice [1]. |
Molecular Weight | 1064.08 |
Formula | C37H60F3N13O16S2 |
keep away from moisture
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
iRGD peptide 1 TFA inhibitor inhibit